Pharmacologic Rescue of Motivational Deficit in an Animal Model of the Negative Symptoms of Schizophrenia
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background Deficits in incentive motivation, the energizing of behavior in pursuit of a goal, occur in many psychiatric disorders including schizophrenia. We previously reported deficits in both cognition and incentive motivation in a transgenic mouse model of increased striatal-specific dopamine D2 receptor density (D2R-OE mice (1)). This molecular alteration is observed in patients with schizophrenia, making D2R-OE mice a suitable system to study of the cellular and molecular mechanisms of motivation and avolition, as well as a tool for testing potential therapies against motivational deficits. Methods Behavioral studies using operant conditioning methods were performed both to further characterize the incentive motivation deficit in D2R-OE mice, and test a novel pharmacological treatment target which arose from an unbiased expression study performed using gene chips and was validated by quantitative RT-PCR, in situ hybridization and immunohistochemistry. Results The D2R-OE mice’s reluctance to work is due neither to intolerance for low rates of reward, decreased reactivity to reward, nor increased sensitivity to satiety or fatigue, but to a difference in willingness to work for reward. As in patients with schizophrenia, this deficit was not ameliorated by D2R blockade, suggesting that reversal of the motivational deficit by switching off the transgene results from molecular changes downstream of D2R overexpression. We observed a reversible increase in 5-HT2C receptor expression in D2R-OE mice. Systemic injection of a 5-HT2C antagonist increased incentive motivation in D2R-OE and control mice. Conclusions We propose that targeting 5-HT2C receptors may be a useful approach to modulate incentive motivation in psychiatric illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of memory formation through regulated expression of a CaMKII transgene
Mayford, M., Bach, M. E., Huang, Y.-Y., Wang, L., Hawkins, R. D., & Kandel, E. R. (1996) · Science · doi:10.1126/science.274.5293.1678 · Cited by 1,550 · cited 1×
“We crossed transgenic mice that express D2R under the tetracycline response element (tetO) to mice expressing the tetracycline transactivator, tTA, under the CamKIIa promoter (7).”
BackgroundSelf-citationSurmeier, D. J., Ding, J., Day, M., Wang, Z., & Shen, W. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.008 · Cited by 1,203
Kellendonk, C., Simpson, E. H., Polan, H. J., Malleret, G., Vronskaya, S., Winiger, V., Moore, H., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.023 · Cited by 520 · cited 5×
“To model the increase in density of striatal D2 receptors (D2Rs) observed in patients with schizophrenia, we previously generated transgenic mice in which D2Rs are selectively overexpressed in the striatum in a temporally controllable manner (D2R-OE mice) (1).”
BackgroundMethodInfluentialSelf-citationThe cognitive neuroscience of schizophrenia.
Barch, D. M. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143959 · Cited by 437
Negative symptoms of schizophrenia: a problem that will not go away
Stahl, S. M., & Buckley, P. F. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00947.x · Cited by 195 · cited 1×
“Clinical data suggests that the motivational deficits observed in patients with schizophrenia are not significantly ameliorated by treatment with D2R antagonists (16).”
Background
Cited by
Salamone, J. D., Yohn, S. E., López-Cruz, L., San Miguel, N., & Correa, M. (2016) · Brain · doi:10.1093/brain/aww050 · Cited by 350
Millan, M. J., Fone, K., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 347
Barch, D. M., Pagliaccio, D., & Luking, K. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_376 · Cited by 218
Increasing dopamine D2 receptor expression in the adult nucleus accumbens enhances motivation
Trifilieff, P., Feng, B., Urizar, E., Winiger, V, Ward, R. D., Taylor, K. M., Martinez, D., Moore, H., Balsam, P. D., Simpson, E. H., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.57 · Cited by 206
Self-citationMesolimbic Dopamine and the Regulation of Motivated Behavior
Salamone, J. D., Pardo, M., Yohn, S. E., López-Cruz, L., SanMiguel, N., & Correa, M. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_383 · Cited by 204
Metadata
- Authors
- Simpson, E. H., Kellendonk, C., Ward, R. D., Richards, V., Lipatova, O., Fairhurst, S., Kandel, E. R., & Balsam, P. D.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 69
- Issue
- 10
- Pages
- 928-935
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2089871324
- Cited by
- 84
- References
- 5
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic Rescue of Motivational Deficit in an Animal Model of the Negative Symptoms of Schizophrenia. https://app.cochat.ai/papers/10.1016/j.biopsych.2011.01.012
- The paper
- Simpson, E. H., Kellendonk, C., Ward, R. D., Richards, V., Lipatova, O., Fairhurst, S., Kandel, E. R., & Balsam, P. D. (2011). Pharmacologic Rescue of Motivational Deficit in an Animal Model of the Negative Symptoms of Schizophrenia. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2011.01.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.